Gossamer Bio Inc
GOSS3.230USD
-0.210-6.10%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
747.12MMarket Cap
LossP/E TTM
More Details of Gossamer Bio Inc Company
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Gossamer Bio Inc Info
Ticker SymbolGOSS
Company nameGossamer Bio Inc
IPO dateFeb 08, 2019
CEOHasnain (Faheem)
Number of employees144
Security typeOrdinary Share
Fiscal year-endFeb 08
Address3115 Merryfield Row
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18586841300
Websitehttps://www.gossamerbio.com/
Ticker SymbolGOSS
IPO dateFeb 08, 2019
CEOHasnain (Faheem)
Company Executives of Gossamer Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
557.79K
+363.70%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
368.45K
+78.90%
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
174.83K
+250.84%
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
58.05K
+81.41%
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Mr. Russell J. Cox
Mr. Russell J. Cox
Independent Director
Independent Director
7.20K
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Ob) Smith
Mr. Robert (Ob) Smith
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Steven D. Nathan, M.D.
Dr. Steven D. Nathan, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
557.79K
+363.70%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
368.45K
+78.90%
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
174.83K
+250.84%
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
58.05K
+81.41%
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
7.82%
Octagon Capital Advisors LP
7.37%
BlackRock Institutional Trust Company, N.A.
5.42%
The Vanguard Group, Inc.
5.19%
ARCH Venture Partners
3.48%
Other
70.73%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
7.82%
Octagon Capital Advisors LP
7.37%
BlackRock Institutional Trust Company, N.A.
5.42%
The Vanguard Group, Inc.
5.19%
ARCH Venture Partners
3.48%
Other
70.73%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.33%
Investment Advisor
21.76%
Venture Capital
14.06%
Investment Advisor/Hedge Fund
12.12%
Corporation
2.71%
Research Firm
1.94%
Private Equity
1.65%
Individual Investor
1.22%
Bank and Trust
0.10%
Other
18.12%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
269
178.21M
76.99%
-56.62M
2025Q2
264
183.64M
80.76%
-59.32M
2025Q1
285
180.17M
79.28%
-64.51M
2024Q4
310
181.35M
80.03%
-59.94M
2024Q3
354
184.99M
81.77%
-80.44M
2024Q2
354
192.00M
84.87%
-65.92M
2024Q1
360
205.91M
94.29%
-56.87M
2023Q4
359
215.74M
99.04%
-22.98M
2023Q3
360
211.40M
97.17%
+97.02M
2023Q2
346
75.83M
79.45%
-49.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
18.09M
7.87%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
18.35M
7.98%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.15M
4.85%
+8.33M
+295.30%
Jun 30, 2025
The Vanguard Group, Inc.
11.41M
4.96%
+1.33M
+13.16%
Jun 30, 2025
ARCH Venture Partners
8.06M
3.5%
--
--
Jun 30, 2025
Samsara BioCapital, LLC
6.13M
2.67%
--
--
Jun 30, 2025
Palo Alto Investors LP
5.74M
2.5%
-537.88K
-8.57%
Jun 30, 2025
Hasnain's family
5.41M
2.35%
+372.00K
+7.39%
Apr 28, 2025
Invus Public Equities Advisors, LLC
5.21M
2.27%
--
--
Jun 30, 2025
683 Capital Management LLC
6.34M
2.76%
+240.00K
+3.93%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
0.21%
Vanguard US Momentum Factor ETF
0.09%
iShares Micro-Cap ETF
0.09%
iShares Russell 2000 Growth ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Proshares Ultra Russell 2000
0.02%
ProShares UltraPro Russell2000
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
View more
ALPS Medical Breakthroughs ETF
Proportion0.21%
Vanguard US Momentum Factor ETF
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.09%
iShares Russell 2000 Growth ETF
Proportion0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Gossamer Bio Inc?
The top five shareholders of Gossamer Bio Inc are:
New Enterprise Associates (NEA) holds 18.09M shares, accounting for 7.87% of the total shares.
Octagon Capital Advisors LP holds 18.35M shares, accounting for 7.98% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.15M shares, accounting for 4.85% of the total shares.
The Vanguard Group, Inc. holds 11.41M shares, accounting for 4.96% of the total shares.
ARCH Venture Partners holds 8.06M shares, accounting for 3.50% of the total shares.
New Enterprise Associates (NEA) holds 18.09M shares, accounting for 7.87% of the total shares.
Octagon Capital Advisors LP holds 18.35M shares, accounting for 7.98% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.15M shares, accounting for 4.85% of the total shares.
The Vanguard Group, Inc. holds 11.41M shares, accounting for 4.96% of the total shares.
ARCH Venture Partners holds 8.06M shares, accounting for 3.50% of the total shares.
What are the top three shareholder types of Gossamer Bio Inc?
The top three shareholder types of Gossamer Bio Inc are:
New Enterprise Associates (NEA)
Octagon Capital Advisors LP
BlackRock Institutional Trust Company, N.A.
New Enterprise Associates (NEA)
Octagon Capital Advisors LP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Gossamer Bio Inc (GOSS)?
As of 2025Q3, 269 institutions hold shares of Gossamer Bio Inc, with a combined market value of approximately 178.21M, accounting for 76.99% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.77%.
What is the biggest source of revenue for Gossamer Bio Inc?
In --, the -- business generated the highest revenue for Gossamer Bio Inc, amounting to -- and accounting for --% of total revenue.
